边缘区淋巴瘤的治疗
本文综述边缘区淋巴瘤(MZL)的治疗现状:MZL发病率较低,关键随机试验对MZL亚组把握度不足,Lugano分类可能未充分涵盖部分亚型的表现或治疗反应,当前治疗多基于单臂研究。早期与晚期一线策略可实现持久疾病控制,复发难治阶段有效选择有限。CD3×CD20双特异性抗体与抗体偶联药物显示出 encouraging 的深度缓解疗效,循环肿瘤DNA在风险分层与分子学反应监测方面具有潜力。
要点
- MZL治疗进展缓慢,仅单个获美国食品药品监督管理局批准的药物影响治疗格局。
- 关键随机惰性淋巴瘤试验中MZL亚组把握度不足,难以捕捉组间差异。
- 当前MZL治疗多依据单臂研究,药物间序贯治疗多属经验性。
核心结论
- 当前MZL治疗多由单臂研究提供依据,现有药物间序贯治疗多属经验性。
- 早期与晚期MZL一线策略可实现持久疾病控制,但复发难治阶段能取得相似结果的选择有限。
- 新兴数据显示CD3×CD20双特异性抗体与抗体偶联药物在实现深度缓解方面具有鼓舞性疗效,循环肿瘤DNA在风险分层与分子学反应监测方面具有潜力。
- MZL是异质性疾病群,各亚型在生物学、临床表现、治疗反应、毒性与生存方面各具特征,但普遍呈惰性病程。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- MZL发病率较低是治疗进展缓慢的重要因素之一。
- 关键随机惰性淋巴瘤临床试验分析MZL亚组时把握度不足,无法捕捉治疗组间差异。
- 当前Lugano分类可能未充分反映部分MZL亚型的表现或治疗反应,妨碍入组临床试验并限制跨疾病谱的疗效评估。
- 早期与晚期MZL一线策略可实现持久疾病控制,而复发难治阶段鲜有能取得相似结果的选项。
- CD3×CD20双特异性抗体与抗体偶联药物在实现深度缓解方面显示鼓舞性疗效,循环肿瘤DNA在风险分层与分子学反应监测方面具有潜力。
关键数值与推荐
- 原文未报告具体疗效数值或推荐条款。
临床怎么用
- 原文未据此给出推荐。
局限性
- MZL发病率较低,影响研究推进。
- 关键随机惰性淋巴瘤临床试验中MZL亚组把握度不足,无法捕捉治疗组间差异。
- 当前Lugano分类可能未充分反映部分亚型的表现或治疗反应,妨碍临床试验入组并限制跨疾病谱疗效评估。
- 当前MZL治疗多依据单臂研究,药物间序贯治疗多属经验性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment landscape of B-cell non-Hodgkin lymphomas is rapidly evolving. However, few advances have occurred in marginal zone lymphoma (MZL), with a single US Food and Drug Administration-approved agent impacting the treatment landscape. Multiple factors are associated with this slower pace of progress, with a lower MZL incidence representing a significant factor. Pivotal randomized indolent lymphoma clinical trials analyzed MZL subsets without the appropriate power to capture differences between treatment arms. Furthermore, the current Lugano classification may not fully capture the presentation or treatment responses of some subtypes, preventing access to clinical trials and limiting an efficacy assessment across the disease spectrum. Thus, current MZL treatment is largely informed by single-arm studies with relatively empiric treatment sequencing among available agents. Although frontline strategies in early and advanced-stage MZL can achieve prolonged disease control, few options exist in the relapsed/refractory setting capable of achieving similar results. Emerging data demonstrate the encouraging efficacy of CD3×CD20 bispecific antibodies and antibody-drug conjugates in achieving deep responses, as well as the potential of circulating tumor DNA in risk stratification and molecular response monitoring. Compounding all these considerations, it is essential to recognize MZL as a heterogeneous group of diseases characterized by unique biology, clinical presentation, treatment response, toxicity, and survival. Nonetheless, a common characteristic across MZL subtypes is their general indolent disease course, emphasizing the need to incorporate patient-centered assessment in clinical trials to better inform the decision-making process.
引用
- Alderuccio JP, Noy A. The treatment of marginal zone lymphoma. Blood. 2026. PMID: 40663786. doi:10.1182/blood.2024028269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。